Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort have?
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort has 75 citations in the OpenAlex counts ScholarIQ stores.
When was Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort published?
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort has 2020 year in the ScholarIQ index.
What is the open-access status of Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort?
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort has closed oa status in the ScholarIQ index.
What is the DOI of Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort?
The DOI for Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort is on the source record.
What is the PMID of Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort?
The PMID for Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort is on the source record.
What is the OpenAlex record for Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort?
The OpenAlex for Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort is on the source record.